The role of systemic and immunotherapy in metastatic vulvar and vaginal cancer Stellenwert der Systemtherapie und der Immuntherapie beim metastasierten Vulva- und Vaginalkarzinom
Schwab R, Gaß P (2024)
Publication Type: Journal article
Publication year: 2024
Journal
DOI: 10.1007/s00761-024-01524-z
Abstract
Compared to other tumor entities in women, the incidence of vulvar and vaginal cancer is low. For this reason, the evidence base for systemic therapy in the metastatic situation is limited. A current selective literature search of full publications confirms that often only small phase I/II studies are available for vulvar cancer or can benefit from the data situation for cervical cancer if these results are transferred to both tumor entities. Chemotherapy should always contain platinum in first-line treatment. There are also immuno-oncological approaches with checkpoint inhibitors with good response rates and prolonged survival. Other approaches such as antibody–drug conjugates (ADCs), vaccination, or chimeric antigen receptor T‑cell (CAR-T) therapies are still the subject of research.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Schwab, R., & Gaß, P. (2024). The role of systemic and immunotherapy in metastatic vulvar and vaginal cancer Stellenwert der Systemtherapie und der Immuntherapie beim metastasierten Vulva- und Vaginalkarzinom. Die Onkologie. https://doi.org/10.1007/s00761-024-01524-z
MLA:
Schwab, Roxana, and Paul Gaß. "The role of systemic and immunotherapy in metastatic vulvar and vaginal cancer Stellenwert der Systemtherapie und der Immuntherapie beim metastasierten Vulva- und Vaginalkarzinom." Die Onkologie (2024).
BibTeX: Download